Hirudin: The Promising Antithrombotic

Cardiovascular Drug Reviews

Volumn 10, Issue 2, 1992, Pages 211-232

  Markwardt, Fritz ^a  

^a Medical Academy Erfurt ^*  (Germany)

Author keywords

Antithrombotic; Hirudin; Preclinical and clinical studies

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRUDIN; THROMBIN; THROMBOMODULIN;

ANTICOAGULATION; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EXTRACORPOREAL CIRCULATION; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBIN TIME; THROMBOCYTE; THROMBOSIS; VEIN THROMBOSIS;

EID: 0026693798     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1992.tb00247.x     Document Type: Article

References (142)

1. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits
2. Hirudin
3. r‐Hirudin effects on various platelet functions [Abstract]
4. Hirudin from leech heads and whole leeches and pseudohirudin from leech bodies
5. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration
6. Hirudin, a new therapeutic tool
7. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons
8. Thrombin‐induced aggregation of lymphocytes; non‐enzymic induction by an hirudin blocked thrombin exosite
9. use of site‐directed mutagenesis to investigate the basis for the specificity of hirudin
10. Neutralization of hirudin anticoagulant action by DIP‐thrombin
11. Hirudin in haemodialysis
12. Prevention of experimental coronary thrombosis by hirudin
13. The functional domain of hirudin, a thrombin‐specific inhibitor
14. The critical role of thrombin in arterial thrombosis is demonstrated by hirudin [Abstract]
15. Point mutation modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin
16. Use of fragments of hirudin to investigate thrombin‐hirudin interaction
17. Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA
18. The complete covalent structure of hirudin. Localization of the disulfide bonds
19. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin
20. Do we need to neutralize hirudin's anticoagulant effects to minimize bleeding [Abstract]
21. Neutralization of recombinant hirudin: some practical considerations
22. Development perspectives for recombinant hirudin as an antithrombotic agent
23. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent
24. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats
25. Hirudin and platelets
26. Adrenalin‐induced reactions of human platelets in hirudin plasma
27. Studies on thrombin‐induced endothelium‐dependent vascular effects
28. Platelet functions in recombinant hirudin‐anticoagulated blood
29. Assay of hirudin in plasma using a chromogenic thrombin substrate
30. Crystal structure of the thrombin‐hirudin complex: a novel mode of serine protease inhibition
31. Influence of hirudin on the consumption of antithrombin III in experimental DIC
32. Effect of heparin, hirudin and a synthetic thrombin inhibitor on antithrombin III in thrombin‐induced disseminated intravascular coagulation in rats
33. Identification by HPLC analysis of the unaltered forms of hirudin and desulfated hirudin after kidney passage [Abstract]
34. Evidence for the identity of hirudin isolated after kidney passage with the starting material
35. Effects of thrombin inhibition on the development of the acute platelet‐thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor
36. Hirudo medicinalis and hirudin
37. Inhibition of the thrombin‐platelet reaction by hirudin
38. Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin‐induced intravascular coagulation and acute lung injury in pigs
39. Effect of thrombomodulin on the kinetics of the interaction of thrombin and inhibitors
40. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC)
41. Thrombin inhibition by covalently bound hirudin
42. Inhibition of coagulation and thrombin‐induced platelet activities by a synthetic dodecapeptide modeled on the carboxy‐terminus of hirudin
43. r‐DNA‐hirudin infusion inhibits acute platelet thrombus formation in dog coronary arteries [Abstract]
44. Anticoagulant and antithrombotic actions of recombinant hirudin
45. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors
46. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin
47. Comparative studies of r‐hirudin and heparin on arterial reocclusion after experimental thrombolysis with streptokinase and r‐tPA [Abstract]
48. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis
49. Hirudin interruption of heparin‐resistant arterial thrombus formation in baboons
50. Toxicology of hirudin
51. Studies in toxicity of recombinant hirudin [Abstract]
52. Influence of recombinant hirudin on the thrombogenicity of prothrombin complex concentrates
53. Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin
54. 45‐65
55. Antithrombotic effects of three thrombin inhibitors in a rat model of laser‐induced thrombosis
56. Radioimmunoassay for the detection of active‐site specific thrombin inhibitors in biological fluids
57. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma
58. Hirudines
59. Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity
60. Design and characterization of hirulogs: a novel class of biovalent peptide inhibitors of thrombin
61. Recombinant hirudin: genetic engineering and structure analysis
62. Untersuchungen über Hirudin
63. Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo
64. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins
65. Die Isolierung und chemische Charakterisierung des Hirudins
66. Die Bestimmung des Thrombins durch Titration mit Hirudin
67. Versuche zur pharmakologischen charakterisierung des Hirudins
68. Hirudin, der blutgerinnungshemmende Wirkstoff des medizinischen Blutegels
69. Der Hirudintoleranztest
70. Hirudin as an inhibitor of thrombin
71. Hirudin—Biochemisch‐pharmakologische Wirkung und Anwendung zur gerinnungsphysiologischen Diagnostik
72. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent
73. Prevention of coronary thrombosis by hirudin
74. Biochemistry and pharmacology of hirudin
75. Anticoagulants after thrombolysis
76. Development of hirudin as an antithrombotic agent
77. Prospective clinical use of hirudin as an anticoagulant
78. Le génie génétique conduit au retour de l'hirudine comme anticoagulant
79. Past, present and future of hirudin
80. The comeback of hirudin as an antithrombotic agent
81. The development of hirudin as an anticoagulant agent
82. Pharmacological survey of recombinant hirudin
83. Pharmacological studies on the antithrombotic action of hirudin in experimental animals
84. Influence of thrombin inhibitors on the thrombin‐induced activation of human blood platelets
85. Pharmacokinetics of recombinant hirudin in primates [Abstract]
86. Pharmacological modification of mechanical and electrical responses of frog heart to thrombin
87. Studies on antithrombotic effects of recombinant hirudin
88. Hirudin as anticoagulant in experimental haemodialysis
89. Comparative studies on thrombin inhibitors in experimental microthrombosis
90. Clinical pharmacology of recombinant hirudin
91. Pharmacokinetics and anticoagulant effect of hirudin in man
92. Clinicopharmacological studies with recombinant hirudin
93. Studies on the pharmacokinetics of hirudin
94. Preparation of dextran‐bound recombinant hirudin and its pharmacokinetic behaviour
95. Antithrombin effects of native and recombinant hirudins
96. The hirudin standard
97. Die Reaktion zwischen Hirudin und Thrombin
98. Reindarstellung und Analyse des Thrombininhibitors Hirudin
99. The pharmacology of recombinant hirudin, a new anticoagulant
100. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r‐tPA‐induced thrombolysis
101. Pharmacokinetics of hirudin
102. Pharmacology of r‐hirudin in renal impairment
103. Influence of hirudin on endotoxin‐induced disseminated intravascular coagulation (DIC) in weaned pigs
104. Hirudin in disseminated intravascular coagulation
105. Pharmacokinetic studies with recombinant hirudin in dogs
106. Comparative study on the in vitro effectiveness of antithrombotic agents
107. 125I‐hirudin in rats and dogs
108. 125I‐Markierung von Hirudin
109. Plasma level of dextran‐r‐hirudin
110. Reocclusion after thrombolysis: a problem solved by hirudin
111. The structure of a complex of recombinant hirudin and human α‐thrombin
112. Angiographic and pathologic study of the effect of recombinant desulphatohirudin on restenosis following balloon angioplasty in rabbits [Abstract]
113. Primary structures of new “iso‐hirudins”
114. Preparation of monoclonal antibodies to hirudin and hirudin peptides
115. Der Hirudintest, eine Mikromethode zur Kontrolle des Prothrombinspiegels bei der Antikoagulantientherapie
116. Thrombin‐cellular interaction
117. Hirudin prevents intravascular coagulation in porcine endotoxin shock
118. Chromogenic substrate assay for determination of hirudin in plasma
119. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids
120. Quantitative enzyme‐linked immunosorbent assay (ELISA) for hirudin
121. Laboratory use of hirudin
122. Kinetics of the inhibition of thrombin by hirudin
123. Methods for determination of hirudin
124. Structure‐activity relationships of recombinant hirudins
125. Biology of recombinant hirudin (DGP 39393): a new prospect in the treatment of thrombosis
126. Recombinant desulphatohirudin (DGP 39393): anticoagulant and antithrombotic properties in vivo
127. Hirudin, a probe to analyze the growth promoting activity of thrombin in fibroblasts; reevaluation of the temporal action of competence factors
128. Erste klinische Erfahrungen mit Hirudin
129. Preliminary clinical reports on the antithrombotic action of hirudin [Abstract]
130. Clinical use of hirudin
131. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model
132. Comparative studies on various assays for the laboratory evaluation of r‐hirudin
133. Recombinant hirudin as antithrombotic agent
134. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations
135. Untersuchungen zur Affinitätschromatographie von Hirudin an trägerfixiertem Thrombin
136. Über den Einsatz des spezifischen Thrombin‐Inhibitors Hirudin für diagnostische und biochemische Untersuchungen
137. Isolation and characterisation of hirudin from Hirudo medicinalis
138. Biochemical and pharmacological properties of recombinant hirudin
139. Biochemische und pharmakologische Aspekte des Thrombininhibitors Hirudin
140. On the isolation of the thrombin inhibitor hirudin
141. Contribution of the N‐terminal region of hirudin to its interaction with thrombin
142. Clot‐bound thrombin is protected from inhibition by heparin‐antithrombin III but is susceptible to inactivation by antithrombin III‐independent inhibitors